TOMMY-HILFIGER
31.8.2020 08:02:04 CEST | Business Wire | Press release
Tommy Hilfiger, which is owned by PVH Corp. [NYSE:PVH] announces Make it Possible, a bold approach to environmental and social sustainability that reinforces the organization’s commitment to create fashion that ‘Wastes Nothing and Welcomes All’. With Make it Possible, Tommy Hilfiger is initially committing to 24 ambitious targets centered around circularity and inclusivity, outlined across four pillars towards 2030:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200830005002/en/
- Circle Round: Make products to be fully circular, and part of a sustainable loop.
- Made for Life: Operate with sensitivity to planetary boundaries, for instance in the areas of climate change, land use, freshwater and chemical pollution, from what we buy to where we sell.
- Everyone Welcome: Be a brand that works for every TOMMY Fan – always inclusive, completely accessible.
- Opportunity for All: Create equal access to opportunity – no barriers to success at Tommy Hilfiger.
Tommy Hilfiger’s program is powered by parent company PVH Corp’s Forward Fashion strategy, a set of 15 priorities designed to reduce negative impacts to zero, increase positive impacts to 100%, and improve the over 1 million lives across the company’s value chain.
“I opened my first store, People’s Place, in 1969 in my hometown of Elmira for people of all backgrounds to come together and share exciting pop culture experiences,” said Tommy Hilfiger. “As our brand has evolved over the years, driven by this inclusive spirit, so has our commitment to social and environmental sustainability. With Make it Possible, we will go even further with our commitment. We’re working towards our vision with the entire organization focused on it and, while we’re not there yet, we are going to get there.”
“In these times of health, human, environmental and economic crisis, we share a responsibility to find innovative solutions that will encourage inclusivity and build a more circular future,” said Martijn Hagman, CEO, Tommy Hilfiger Global and PVH Europe. “It is in our nature to drive change, even in the most challenging of times, which is why we are announcing our ambitious Make it Possible sustainability program, outlining 24 targets towards 2030. Tommy Hilfiger has a decade’s long track-record for driving a more sustainable future, including pioneering low impact denim processes, championing water stewardship, and creating more inclusive collections. Make it Possible is one way we will work together to make a meaningful and lasting contribution towards a better fashion industry.”
Make it Possible marks the latest milestone in Tommy Hilfiger’s sustainability journey. Key achievements include the launch of Tommy Hilfiger Adaptive , designed to make dressing easier for adults and children with disabilities, and the Tommy Hilfiger Fashion Frontier Challenge , a global program aimed to support start-up and scale-up stage businesses developing solutions that promote inclusivity and sustainability in fashion. More recently Tommy Hilfiger launched People’s Place Program to advance the representation of black, indigenous and people of color (BIPOC) communities within the fashion and creative industries. To date, more than 80% of Tommy Hilfiger designers have been trained on circular design strategies and, in 2019, 72% of cotton used globally came from more sustainable sources. Additionally 2 million pieces of denim have been finished in lower impact, reducing the amount of water and energy used. Each seasonal TOMMY HILFIGER collection includes more sustainable styles in its collections, as evidenced by the 50% more sustainable styles planned for Spring 2021, double the amount from Spring 2020.
Recognizing that no one company can change the sustainability landscape alone, Tommy Hilfiger, as part of PVH Corp., has joined forces with industry partners by signing The Fashion Pact in August 2019, as well as joining the Ellen MacArthur Foundation Make Fashion Circular and Jeans Redesign initiatives. For the past several years, Tommy Hilfiger has partnered with the WWF to address water risk in our strategic supply chain locations. This includes training on water risk management for suppliers and industrial parks in China’s Taihu River Basin and serving as the founding brand partner of a new water stewardship program in Vietnam in the Mekong basin.
Throughout its journey, Tommy Hilfiger will share its progress. For more information on Make it Possible and a full overview of achievements to date, visit: http://sustainability.tommy.com .
About Tommy Hilfiger
With a brand portfolio that includes TOMMY HILFIGER
and TOMMY JEANS
, Tommy Hilfiger is one of the world’s most recognized premium designer lifestyle groups. Its focus is designing and marketing high-quality men’s tailored clothing and sportswear, women’s collection apparel and sportswear, kidswear, denim collections, underwear (including robes, sleepwear and loungewear), footwear and accessories. Through select licensees, Tommy Hilfiger offers complementary lifestyle products such as eyewear, watches, fragrance, swimwear, socks, small leather goods, home goods and luggage. The TOMMY JEANS
product line consists of jeanswear and footwear for men and women, accessories, and fragrance. Merchandise under the TOMMY HILFIGER
and TOMMY JEANS
brands is available to consumers worldwide through an extensive network of TOMMY HILFIGER
and TOMMY JEANS
retail stores, leading specialty and department stores, select online retailers, and at tommy
.com
.
About PVH Corp.
PVH is one of the most admired fashion and lifestyle companies in the world. We power brands that drive fashion forward – for good. Our brand portfolio includes the iconic CALVIN KLEIN
, TOMMY HILFIGER
, Van Heusen
, IZOD
, ARROW, Warner’s
, Olga
and Geoffrey Beene
brands, as well as the digital-centric True&Co.
intimates brand. We market a variety of goods under these and other nationally and internationally known owned and licensed brands. PVH has over 40,000 associates operating in over 40 countries and $9.9 billion in annual revenues. That's the Power of Us. That’s the Power of PVH.
Follow us on Facebook , Instagram , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200830005002/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
